Ascendis Pharma A/S (ASND) Financial Ratios
14 years of historical data (2012–2025) · Healthcare · Biotechnology
EV/EBITDA
N/A
—
5yr avg: N/A
P/FCF
285.69
-4% vs avg
5yr avg: 296.28
P/B Ratio
↑
N/A
—
5yr avg: 17.17
30Y Low3.0·High26.0
ROE
↓
N/A
—
5yr avg: -321.6%
30Y Low-102%·High104%
Debt/EBITDA
N/A
—
5yr avg: N/A
30Y Low0.1·High0.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
ASND Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
Ascendis Pharma A/S currently has a negative P/E ratio, indicating the company is operating at a loss on a trailing-twelve-month basis. On a free-cash-flow basis, the stock trades at 285.7x P/FCF, roughly in line with the 5-year average of 296.3x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $14.3B | $12.9B | $8.0B | $7.1B | $6.8B | $7.4B | $8.4B | $6.5B | $2.6B | $1.3B | $538M |
| Enterprise Value | $14.6B | $13.2B | $8.3B | $7.4B | $7.0B | $7.1B | $7.9B | $5.9B | $2.3B | $1.2B | $357M |
| P/E Ratio → | -55.72 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 18.02 | 18.68 | 21.92 | 26.58 | 133.82 | 947.34 | 1214.13 | 483.74 | 243.27 | 880.44 | 116.73 |
| P/B Ratio | — | — | — | — | 26.00 | 8.34 | 10.07 | 10.84 | 9.19 | 7.20 | 3.04 |
| P/FCF | 285.69 | 296.28 | — | — | — | — | — | — | — | — | — |
| P/OCF | 240.71 | 249.64 | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
ASND EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 19.05 | 22.73 | 27.90 | 137.20 | 916.96 | 1143.29 | 441.76 | 217.00 | 752.76 | 77.58 |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | 302.15 | — | — | — | — | — | — | — | — | — |
ASND Profitability
Margins and return-on-capital ratios measuring operating efficiency
Ascendis Pharma A/S earns an operating margin of -18.9%. Operating margins have expanded from -170.8% to -18.9% over the past 3 years, signaling improving operational efficiency.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 85.1% | 85.1% | 87.8% | 83.4% | 76.3% | 54.7% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| Operating Margin | -18.9% | -18.9% | -76.7% | -170.8% | -1097.9% | -5808.6% | -4755.1% | -1695.1% | -1462.6% | -7290.3% | -1583.2% |
| Net Profit Margin | -31.7% | -31.7% | -104.0% | -180.5% | -1139.6% | -4931.6% | -6025.5% | -1630.0% | -1229.5% | -8097.8% | -1487.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | -818.4% | -101.7% | -44.5% | -58.4% | -49.7% | -55.7% | -68.1% | -46.1% |
| ROA | -17.7% | -17.7% | -37.7% | -50.3% | -53.6% | -37.2% | -50.6% | -43.8% | -49.1% | -61.8% | -42.6% |
| ROIC | -69.1% | -69.1% | -105.4% | -106.5% | -77.8% | -68.2% | -129.9% | -899.3% | -5304.7% | — | — |
| ROCE | -51.9% | -51.9% | -154.6% | -197.2% | -82.8% | -47.3% | -42.5% | -49.9% | -66.2% | -61.3% | -49.1% |
ASND Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
Net debt stands at $256M ($871M total debt minus $616M cash).
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | 2.35 | 0.24 | 0.11 | 0.06 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | — | — | — | 0.66 | -0.27 | -0.59 | -0.94 | -0.99 | -1.04 | -1.02 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | 5.86 | — | — | — | — | — | — | — | — | — |
| Interest Coverage | -1.69 | -1.69 | -4.70 | -9.76 | -17.83 | -97.17 | -217.55 | -177.75 | -1026.49 | -1281.21 | -13745.40 |
ASND Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
A current ratio of 1.04x means Ascendis Pharma A/S can comfortably meet its short-term obligations, though there is limited excess liquidity. The current ratio has improved from 0.95x to 1.04x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.04 | 1.04 | 1.17 | 0.95 | 1.29 | 8.03 | 14.02 | 12.74 | 7.53 | 8.61 | 13.67 |
| Quick Ratio | 0.76 | 0.76 | 0.84 | 0.67 | 1.11 | 7.28 | 14.02 | 12.74 | 7.53 | 8.61 | 13.67 |
| Cash Ratio | 0.58 | 0.58 | 0.62 | 0.54 | 1.03 | 6.80 | 13.61 | 12.46 | 7.14 | 8.22 | 13.40 |
| Asset Turnover | — | 0.53 | 0.31 | 0.32 | 0.05 | 0.01 | 0.01 | 0.02 | 0.03 | 0.01 | 0.02 |
| Inventory Turnover | 0.34 | 0.34 | 0.15 | 0.21 | 0.09 | 0.05 | — | — | — | — | — |
| Days Sales Outstanding | — | 83.18 | 166.90 | 49.09 | 84.95 | 103.24 | 20.32 | 21.94 | 0.21 | 44.85 | 22.74 |
ASND Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Ascendis Pharma A/S returns 0.1% to shareholders annually primarily through share buybacks.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | 0.4% | 0.3% | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.1% | 0.1% | 0.0% | 0.0% | 1.5% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Total Shareholder Yield | 0.1% | 0.1% | 0.0% | 0.0% | 1.5% | 0.3% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Shares Outstanding | — | $61M | $58M | $56M | $56M | $55M | $51M | $47M | $41M | $34M | $27M |
Peer Comparison
Compare ASND with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 ASNDYou | $14B | -55.7 | — | 285.7 | 85.1% | -18.9% | — | -69.1% | — |
 IONS | $12B | -31.1 | — | — | 98.3% | -40.5% | -70.7% | -12.8% | — |
 INCY | $20B | 15.3 | 11.6 | 14.5 | 91.5% | 26.1% | 29.9% | 51.1% | 0.0 |
 ALKS | $7B | 31.5 | 22.9 | 15.6 | 86.7% | 17.2% | 14.7% | 18.9% | 0.2 |
 JAZZ | $14B | -38.5 | 23.7 | 10.9 | 88.2% | 5.3% | -8.5% | 2.1% | 7.1 |
 ACAD | $4B | 9.4 | 25.7 | 35.2 | 91.7% | 9.8% | 39.9% | 10.0% | 0.4 |
 RARE | $3B | -4.7 | — | — | 83.8% | -79.5% | -607.5% | -89.4% | — |
 AMRN | $333M | -8.9 | — | 49.4 | 56.6% | -6.5% | -8.2% | -2.9% | — |
 CLDX | $2B | -8.3 | — | — | 100.0% | -19160.0% | -40.6% | -35.2% | — |
 KRYS | $10B | 50.9 | 58.2 | 54.3 | 92.6% | 41.5% | 18.9% | 18.0% | 0.1 |
 ACHC | $2B | -2.0 | 8.3 | — | 17.6% | 11.7% | -41.4% | 5.9% | 4.6 |
| Healthcare Median | — | 22.1 | 14.2 | 18.5 | 63.9% | -4.3% | -32.6% | -11.6% | 3.2 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 14 years · Updated daily
Consensus-Based Analysis Tools
Full Stock Analysis
Deep dive into ASND consensus models and risk factors.
View Analysis
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Check Valuation
Historical Returns
10-year return with dividends reinvested.
Calculate
DCA Calculator
See how regular investing compounds over time.
Run Numbers
Peer Comparison
Compare growth, multiples, and margins vs sector.
Compare
ASND — Frequently Asked Questions
Quick answers to the most common questions about buying ASND stock.
What is Ascendis Pharma A/S's P/E ratio?
Ascendis Pharma A/S's current P/E ratio is -55.7x. This places it at the 50th percentile of its historical range.
Is ASND stock overvalued?
Based on historical data, Ascendis Pharma A/S is trading at a P/E of -55.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
What are Ascendis Pharma A/S's profit margins?
Ascendis Pharma A/S has 85.1% gross margin and -18.9% operating margin.